Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL870972 | 0.66 | — | — | |
| SCHEMBL2162391 | 0.65 | ALDH1A1 (0.36) | ALDH1A1KDM4EHPGDHSD17B10GAA | |
| SCHEMBL5429782 | 0.63 | KDM4E (0.44) | ALDH1A1KDM4EHPGDHSD17B10POLB | |
| SCHEMBL6850246 | 0.62 | KDM4E (0.36) | ALDH1A1KDM4EHPGDHSD17B10POLB | |
| SCHEMBL892819 | 0.60 | ALDH1A1 (0.38) | ALDH1A1KDM4EHPGDHSD17B10GAA | |
| SCHEMBL869773 | 0.60 | RAB9A (0.40) | ALDH1A1KDM4EHPGDHSD17B10GAA | |
| Bromide SCHEMBL3576597 | 0.59 | ALDH1A1 (0.37) | ALDH1A1KDM4EHPGDHSD17B10GAA | |
| SCHEMBL11326257 | 0.58 | ALDH1A1 (0.43) | ALDH1A1KDM4EHPGDHSD17B10GAA | |
| SCHEMBL4554180 | 0.58 | ALDH1A1 (0.36) | ALDH1A1KDM4EHPGDHSD17B10POLB | |
| SCHEMBL15057332 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360156-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-10-31 | — | — | US | disclosed |
| US-11279713-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360156-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | ALDH1A1 177/4885KDM4E 1330/4885HPGD 889/4885 |
| US-11279713-B2 | Heterocyclic compound and use thereof | GRIN1, GRIN2C, GRIN2A | ALDH1A1 177/4885KDM4E 1330/4885HPGD 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.